ALT: Phase III MASH trial enrollment advances, with strong data and financials supporting broad liver disease focus
Management highlighted late-stage progress for pemvidutide in liver diseases, with phase III MASH enrollment underway and strong phase II results in AUD and ALD. Differentiation is driven by dual liver and metabolic action, high patient retention, and robust financials supporting execution.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.